Bepotastine Besilate
Grundinformationen
- CAS
190786-44-8- Standard-SMILES
O=C(O)CCCN1CCC(O[C@@H](c2ccc(Cl)cc2)c2ccccn2)CC1.O=S(=O)(O)c1ccccc1- InChIKey
UDGHXQPQKQPSBB-BOXHHOBZSA-N- Summenformel
- C27H31ClN2O6S
- Durchschnittliche Molmasse
- 547,1 g/mol
- Monoisotopische Masse
- 546,15913539
Überblick
Bepotastine besylate is an organosulfonate salt obtained by combining equimolar amounts of bepotastine and benzenesulfonic acid. A topical, selective and non-sedating histamine (H1) receptor antagonist used for treatment of itching associated with allergic conjunctivitis. It has a role as a H1-receptor antagonist and an anti-allergic agent. It contains a bepotastine(1+).
Namen und Bezeichner
- Bevorzugter Name
- Bepotastine Besilate
- IUPAC
- benzenesulfonic acid;4-[4-[(S)-(4-chlorophenyl)-pyridin-2-ylmethoxy]piperidin-1-yl]butanoic acid
- Englischer Name
- BEPOTASTINE BESILATE
- Summenformel
- C27H31ClN2O6S
- Molmasse
- 547.06
Namen und Synonyme
Bepotastine besilate190786-44-8Bepotastine besylateBepreveTalionBepotastine benzenesulfonateBepotastine Benzenesulfonate Salt6W18MO1QR3CHEBI:31281DTXSID801725771-Piperidinebutanoic acid, 4-[(S)-(4-chlorophenyl)-2-pyridinylmethoxy]-, benzenesulfonate (1:1)1-Piperidinebutanoic acid, 4-((S)-(4-chlorophenyl)-2-pyridinylmethoxy)-, benzenesulfonate (1:1)
Weitere Namen anzeigen
BBCS-645CS-487TAU 284Talion (TN)BenzestatineBetastine besylate
RefChem:567016DTXCID3095068Bepotastine Besilate Ophthalmic Solution 1.5%(S)-4-(4-((4-Chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid monobenzenesulfonateBetotastine besilate(S)-4-(4-((4-chlorophenyl)(pyridin-2-yl)methoxy)piperidin-1-yl)butanoic acid compound with benzenesulfonic acid (1:1)MFCD01938491Bepotastine besylate [USAN]
Datenbank-Bezeichner
- CAS
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 125 Ų
- H-Brücken-Donoren
- 2
- H-Brücken-Akzeptoren
- 8
- Frei drehbare Bindungen
- 9
- Schwere Atome
- 37
- Formalladung
- 0
- Komplexität
- 632
Experimentelle und physikochemische Eigenschaften
Human Drugs
Breast Feeding; Lactation; Milk, Human; Anti-Allergic Agents; Antihistamines
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physikochemische Eigenschaften
- Schmelzpunkt
- 161 · 161-163°
- storage temp.
- Inert atmosphere,Room Temperature
- Löslichkeit
- DMSO (Slightly, Heated), Methanol (Slightly, Heated)
- Aggregatzustand
- Solid
- Farbe
- White to Light Beige
- Stabilität
- Hygroscopic
- InChIKey
- UDGHXQPQKQPSBB-ZMBIFBSDSA-N
- SMILES
- [S](=O)(=O)(O)c4ccccc4.Clc1ccc(cc1)[C@@H](OC3CCN(CC3)CCCC(=O)O)c2ncccc2
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
This chemical does not meet GHS hazard criteria for 33.3% (1 of 3) of reports.
Warning
H361 (33.3%): Suspected of damaging fertility or the unborn child [Warning Reproductive toxicity]
P203, P280, P318, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 3 reports by companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Hazard Classes and CategoriesRepr. 2 (33.3%)
Toxikologische Informationen
Exposure Routes
Oral, Ophthalmic. Tmax, after single dose, opthalmic = 1.2 hours; Cmax, 1.5%, opthalmic dose = 7.3 ± 1.9 ng/mL; After 24 hours post-installation, levels of bepotastine are below quantifiable limit of 2 ng/mL. Minimal systemic absorption with opthalmic dosage form.
Toxicity Summary
Because of a type 1 hypersensitivity reaction cascade that is triggered by antigen exposure, allergic conjunctivitis occurs. Allergen exposure is followed by conjunctival mast cell degranulation and histamine released as a result of the formation of complementary IgE cross-links on the conjunctiva. Due to the release of histamine, symptoms such as itching can be observed. Bepotastine works to relieve itchy eyes by three primary mechanisms of action. It is a non-sedating, selective antagonist of the histamine 1 (H1) receptor, a mast cell stabilizer, and it suppresses the migration of eosinophils into inflamed tissues to prevent tissue damage and worsening of allergic inflammation of the conjunctiva.
Chemie und Industrie
Pharmakologische Informationen
Metabolism/MetabolitesMinimal metabolism via CYP enzymes
Route of Elimination: When a oral dose of 2.5 - 40 mg bepotastine is given, 75%-90% of the dose was excreted unchanged in the urine by 24 hours.
Half Life: Elimination half life = 2.5 hours
FDA Pharmacological Classification
BEPOTASTINE BESILATE
Histamine-1 Receptor Antagonist [EPC]
BEPOTASTINE BESILATE OPHTHALMIC SOLUTION 1.5%
Histamine-1 Receptor Antagonist [EPC]
MeSH Pharmacological Classification
Agents that are used to treat allergic reactions. Most of these drugs act by preventing the release of inflammatory mediators or inhibiting the actions of released mediators on their target cells. (From AMA Drug Evaluations Annual, 1994, p475)
Verwendung und Herstellung
UsesFor the symptomatic treatment of itchy eyes (caused by IgE-induced mast cell degranulation) due to allergic conjunctivitis. Used in the treatment of allergic rhinitis and uriticaria/puritus. [Wikipedia]
Anwendungen
BeschreibungBetotastine was introduced in Japan for the treatment of allergic rhinitis. This structurally-related derivative of chlorpheniramine and ebastine is prepared by condensation of optically-resolved 4-[1-(4-chlorophenyl)-1-(2-pyridyl)-methoxy]piperidine with ethyl 4-bromobutyrate followed by ester hydrolysis. Betotastine is the seventh marketed non-sedating histamine H1 antagonist. Its very low sedative side effect is due to very poor penetration in the central nervous system. Besides its potent and long-acting activity in models of allergic rhinitis, betotastine was also shown to act as a PAF antagonist and inhibit LTD4 in tracheal smooth muscle and ileum, IL-5 production by human peripheral blood mononuclear cells as well as eosinophil infiltration in the airway and peripheral blood. As a consequence, it is currently being developed against other allergic and respiratory disorders.
Zugehörige Reaktionen
3
Notizen zur Verbindung
Wird geladen…